The order escalates trade pressure on drugmakers even as the administration delays a separate rule that could restrict imported medicines from Canada and overse

The deal adds AI-designed multispecific proteins to Zealand's obesity pipeline, though some analysts question the structure and near-term impact.

The pricing deal is projected to save $64.3B over 10 years, with Eli Lilly lowering prices and Novo Nordisk expecting demand to keep rising.

Positive late-stage data lifts psychedelic-therapy names as the sector draws renewed policy attention.

Epe's half-price launch, expected in November at about 130,000 won for the first month, pressures established obesity drug pricing in Korea.

The approval broadens the label for ImmunityBio's Anktiva months ahead of deadline, covering patients whose cancer persists after earlier treatment.

The decision removes one contender from the crowded obesity pipeline as Pfizer faces separate lung cancer trial disappointment.

The pancreatic cancer drug cut the risk of death by 60 percent versus chemotherapy in a trial, drawing bullish analyst targets.

The agency is reshaping its rare disease drug review framework amid leadership and process changes.

The application covers LB2501, a therapy designed to generate immune cells inside the body, an emerging alternative to ex vivo CAR-T manufacturing.

Expanded drug price cuts draw industry backlash and push companies to reassess Japanese R&D spending.

The delay averts near-term supply disruption for imported prescription medicines.

Fragile X has no FDA-approved treatment, and Anavex plans a small adult study after gaining investigational new drug clearance.

Researchers are testing whether GLP-1 drugs have uses beyond weight loss in addiction and mood disorders.

Early data support further development of the company's rare skin cancer therapy.

Analysts split on approval probability as FDA documents paint a difficult picture, sending shares sharply lower.

The failed study removes a near-term catalyst for Vanda's pipeline.

The FDA clearance marks the company's first cancer drug approval, driving a sharp single-day share move.